Medicine & Life Sciences
Parkinson Disease
100%
Randomized Controlled Trials
90%
Language Therapy
35%
Meta-Analysis
32%
Speech Therapy
32%
Placebos
31%
Chronic Renal Insufficiency
31%
Therapeutics
29%
Quality of Life
29%
Cost-Benefit Analysis
28%
Levodopa
28%
Dopamine Agonists
24%
Nephrotic Syndrome
24%
Monoamine Oxidase Inhibitors
23%
Prednisolone
23%
Confidence Intervals
21%
Vasculitis
21%
Melanoma
20%
2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid
20%
Safety
19%
Random Allocation
19%
Pseudotumor Cerebri
16%
Interferons
16%
Renal Artery Obstruction
15%
Patient Reported Outcome Measures
15%
Health Care Outcome Assessment
15%
Plasma Exchange
15%
Monoamine Oxidase
15%
propylene diquat
14%
Botulinum Toxins
14%
Feasibility Studies
14%
Recurrence
14%
Blood Pressure
13%
Steroids
13%
Chlorthalidone
12%
Exercise
12%
Child
12%
Migraine Disorders
12%
Angiotensin Receptor Antagonists
12%
11-beta-Hydroxysteroid Dehydrogenases
11%
Kidney
11%
Angioplasty
11%
Glucocorticoids
11%
Odds Ratio
11%
Respiratory Tract Infections
11%
Survival
10%
Systematic Reviews
10%
Spironolactone
10%
Angiotensin-Converting Enzyme Inhibitors
10%
Quality-Adjusted Life Years
10%